echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Small-molecule targeted drugs compete in the top 10 with Zhengda Tianqing and Hengrui

    Small-molecule targeted drugs compete in the top 10 with Zhengda Tianqing and Hengrui

    • Last Update: 2020-06-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Medicines Network June 3, 2020 to date, China has approved five domestic anti-tumor targeted drugsIn addition to the metasuldonic ametinib and the ealitic schonitencapsulecapsules of Jiangsu Howson Pharmaceuticals, small molecule anti-tumor targeting drugs are also injected with boronitis, Ziru Pharmaceuticals, and Qilu Pharmaceuticals' acetate abitron tabletsDomestic pharmaceutical companies anti-tumor small molecules targeted drugs are gradually launching a shock to the original drug, the market continues to shuffleInventory: 2019domestic small molecules targeted drug market
    with the rapid development of China's largehealthindustry, as well as the demand for precision medicine is changing rapidlyUnder the influence of the trend of aging market in Chinese, many factors make the demand demand of the drug market increase day by day, and promote the growth of the drug market under the impetus of the targeted drug marketTargeted drugs are composed of bioengineered monoclonal antibody drugs and chemical small molecule-targeted drugs, especially small-molecule targeted drugs with the characteristics of easy to use drugs, strong compliance, in the anti-tumor and refractorydiseasesdrug market has attracted attentionAccording to minet data, china's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public health institutions) have reached 149.944 billion yuan in anti-tumor and immunomodulatory drugs in 2019, an increase of 14.20% year-on-year, and China's urban public hospitals have become the main consumer terminals in the anti-tumor and immunomodulator marketAs we all know, targeted drugs are one of the first choice of precision medicine in ChinaAccording to statistics, more than 50 small molecule-targeted drugs have been approved in China, including the independently developed 1 class of small molecule-targeting drugs are Ektini (Cameina), HengruiPharmaceuticals Ofatini (Etan) and Dicureini (Aerini), and Whampoa's furanitinib (Aiut), zheng's sunny Anrotini (Fucovi), Reding Pharmaceuticals' Nirapali (Sulapali), Jiangsu Howson Pharmaceuticals' metasulphate amatinib (Amel) meters net data show that in 2019, the domestic key provinces and cities public hospitals clinical use of small molecular targeted drugs have exceeded 50 chemical varieties, sales reached 12 billion yuan, an increase of 31.04 percent year-on-year, two consecutive years of growth of more than 30 percent   Oxitini EGFR-TKI target a unique in recent years, key provinces and cities public hospitals newly listed small molecule target drug TOP10 varieties (units: million yuan) meters of intranet data show that after 2017, into the key provinces and cities of public hospitals, small molecules targeted drugs have 21 drugs, of which small molecule target drugs TOP10 sales of 2.351 billion yuan, a year-on-year growth rate of 1268.41 percent The first drug is Osimertinib   Ositini is the drug listed by AstraZeneca, named Tagrisso, in November 2015 after the FDA approved AstraZeneca.com In March 2017, the State Drug Administration approved the registration of the commodity name Terisha It is suitable for the treatment of advanced disease during or after treatment of pastepider growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), and the treatment of adult patients with advanced localized or metastatic non-small cell lung cancer (NSCLC) with positive EGFR T790M mutation has been detected   In 2019, Theocini's global market reached $3.189 billion, up 71.45 percent year-on-year, making it a leading astral and accounting for one-third of AstraZeneca's anti-tumor targeting drug sector According to the data of Minet, sales of Oshitini (Terissa) in key provinces and cities in China reached 948 million yuan in 2019, up 40.14% year-on-year   Oxitinib is the preferred treatment for Patients with T790M-positive NSCLC, and in September 2018, the National Health Insurance Administration was included in the health insurance list After 17 cancer drugs were included in the category B coverage, the average decrease was 56.7% In particular, Oxitinib decreased by 71%, from the previous 528,000 yuan / box / month to 153,000 yuan / box / month, improve the patient's drug use, objectively promoted the rapid growth of Terisa   The increase of 1854.59% of the Anrotini capsule stakes amatiani is the independent brand developed by Zhengda Tianqing Pharmaceutical Group, targetING VEGFR, which provides a new option for the third-line treatment of china's late NSCLC On May 8, 2018, it was approved for the market by the State Drug Administration, and the product was named Fuweiwei After negotiations, Anrotini reduced the price by 45% and was successfully included in the National Class B Health Insurance List at a price of 487 yuan per grain (12 mg)   According to the data of Minet, sales of Arottini (Fucovi) in key provinces and cities in China reached 614 million yuan in 2019, up 1854.59 percent from the previous year It is reported that Anrotinib in other cancers to carry out clinical research, including small cell lung cancer, soft tissue sarcoma, esophageal squamous cancer, thyroid cancer and kidney cancer, have obtained good clinical data results, will become the release of Focovi's potential in the market to provide new hope   Imateni is a billion-scale is a tyrosine kinase inhibitor drug developed by Novartis On May 10, 2001, Imatinib received the FDA's express approval for "breakthrough anti-tumor mechanism" under the name "Gleevec" Global Novartis's Greeve sales still reached $1.263 billion in 2019, down 19.09 percent from a year earlier, after sales of more than $70 billion in 2019   Imatinib is used to treat patients with chronic stages of chronic stage serotic, accelerated or alpha-interferon treatment after the treatment of chronic disorders; After the expiration of the patent, domestic imitations have been developed and listed In 2013, Jiangsu Howsen Pharmaceutical Group Imatini film listed, the commodity name Wei In 2014, Itwasani capsules were listed by Zhengda Tianqing Pharmaceutical Group, with the product name Gnico, followed by imatinib tablets of stone pharmaceutical group, and the commodity name Nolinin   With the promotion of the "4 plus 7" collection, Jiangsu Howson produced 100mg x 12 tablets / plates x 1 board / bag x 5 bags (60 tablets) specifications of the generic drug memartiniiv, the winning price is 623.82 yuan meters net data show that in 2019, the domestic key provinces and cities public sample hospital Samartini market of 695 million yuan, in the situation of volume-for-value situation, down 15.73 percent year-on-year, still in the small molecule targeted drugs sales of the third-largest variety   In 2019, Novartis' Grewe accounted for 76.10% of the public sample hospital market in key provinces and cities, down 3.4 percentage points, jiangsu Howson's Weiwei accounted for 17.76 percent, up 5.9 percentage points, Zhengda Tian's Ginico accounted for 5.26 percent, and the stone drug O'Leary's Nolinin accounted for 0.89 percent   In recent years, a number of new batch of small molecule target drug 2018 NMPA approved the listing of small molecule target new drugs
    the State Drug Administration in 2018 approved 10 new small molecule target drugs, in 2019 new approval of 8 small molecule target drugs In 2020, the outbreak of new global coronary pneumonia, the National Drug Administration the Drug Review Center to continue to open the green channel, the new approval of Jiangsu Haussen Pharmaceuticals of the sulfonate amitinib, the United States Pumay, Inc.'s Malayanacid nalitini tablets, Novartis Pharmaceuticals of Switzerland's Sinimod tablets, Teva Pharmaceuticals' niobium   In 2019-May 2020, NMPA approved the listing of small molecules targeting new drugs
    meters of intranet data show that in 2019, the domestic key provinces and cities of public sample hospitaltargetdrug market of nearly 20 billion yuan market size, an increase of 32.88 percent year-on-year, of which antibody-targeted drugs accounted for 40%, small molecule targeted drug market accounted for 60%
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.